These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38074635)

  • 21. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
    Wang P; Xia L
    BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
    Wu X; Xu L; Li X; Zhou Y; Han X; Zhang W; Wang W; Guo W; Liu W; Xu Q; Gu Y
    Cell Death Dis; 2023 Aug; 14(8):550. PubMed ID: 37620320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
    Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
    Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
    Yu J; Fang T; Yun C; Liu X; Cai X
    Front Mol Biosci; 2022; 9():847835. PubMed ID: 35295841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
    Lei H; Ling Y; Yuan P; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Han W; Hu C; Chi Z; Cui C; Si L; Fang J; Guo J; Sheng X; Zhou A; Ying J
    J Natl Cancer Cent; 2023 Jun; 3(2):121-128. PubMed ID: 39035731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
    Tan X; Wang Y; Wu Z; Zhou Q; Tang Y; Liu Z; Yuan G; Luo S; Zou Y; Guo S; Han N; Yao K
    Eur J Cancer; 2023 Nov; 194():113360. PubMed ID: 37862796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
    Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
    Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
    Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
    Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
    [No Abstract]   [Full Text] [Related]  

  • 32. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
    Wang A; Chen M; Li D; Shi J; Tang W; Zhang Z; Ren S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102085. PubMed ID: 38636170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 34. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
    Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
    Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.
    He L; Shen X; Liu Y; Gao L; Wu J; Yu C; Li G; Wang X; Shao X
    Transl Cancer Res; 2022 Nov; 11(11):4206-4217. PubMed ID: 36523304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma.
    Xu Z; Ma J; Chen T; Yang Y
    Front Immunol; 2022; 13():978266. PubMed ID: 36458005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
    Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with
    Qu Y; Liu Y; Ding K; Li Y; Hong X; Zhang H
    Onco Targets Ther; 2021; 14():1581-1588. PubMed ID: 33688205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.